Company Overview and News

1
Rounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based Innovators

2018-04-20 seekingalpha
Shares of Crispr continued to trade further North. The management is gearing up the next growth phase by streamlining its team.
Upvote Downvote

1
Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials

2018-04-19 seekingalpha
The 2nd quarter of 2018 offers investors a number of significant Phase 2 data releases for investors to be aware of before the summer.
Upvote Downvote

 
Rounds Report: Sangamo Rallied While The Fundamentals Of Ultragenyx And Intercept Improved

2018-04-18 seekingalpha
Following the rally of the gene-based therapeutic innovators, Sangamo traded robustly higher during for the day’s session.
Upvote Downvote

6
SGMO / Sangamo BioSciences, Inc. FORM 8-K (Current Report)

2018-04-17 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

1
Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators

2018-04-13 seekingalpha
Geron Corporation caught a big wave, as the stock rallied robustly in the second half of the trading session. Facing two upcoming binary catalysts (events that can make or break).
Upvote Downvote

2
SGMO / Sangamo BioSciences, Inc. 8-K (Current Report)

2018-03-23 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
BioSci Rounds Report: Omeros Rallied, Arcus Insider Purchased, And Spark Treated The First Patient With Luxturna

2018-03-23 seekingalpha
Omeros shares rallied over 35% due to the favorable chances that the spending bill will be passed this Friday.
Upvote Downvote

1
Cellectis' (CLLS) CEO André Choulika on Q4 2017 Results - Earnings Call Transcript

2018-03-13 seekingalpha
Greetings and welcome to the Cellectis Full Year 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
Upvote Downvote

2
Specialty Research: Stellar Gene Therapy And Gene Editing Innovators

2018-03-13 seekingalpha
Luxturna made history as the first FDA-approved gene therapy but there are more gene therapies as well as gene editing innovations to feature this decade.
Upvote Downvote

2
Sangamo Therapeutics Part III: Elucidating The Prospects Of Amyotrophic Lateral Sclerosis

2018-03-09 seekingalpha
Part I research analyzed the overall investment thesis in Sangamo while emphasizing the Kite/Gilead partnership for zinc finger nuclease (“ZFN”) to enhance CAR-Ts.
Upvote Downvote

 
Sangamo Therapeutics - Part II: Is There A Hidden Asset In Play?

2018-03-08 seekingalpha
Sangamo and Case Western University recently received $11M to develop a novel treatment for the Human Immunodeficiency Virus (“HIV”).
Upvote Downvote

 
Spark Therapeutics: Earnings Update For This Core Biotech Holding

2018-03-04 seekingalpha
My last "buy the dip" piece was followed by an all-out implosion (great example of the risks involved in the biotech sector).
Upvote Downvote

5
Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?

2018-02-22 247wallst
When it comes to mid-cap and small-cap biotech stocks, there are two ways shareholders get rewarded ahead of or after big drug development news. One is that the company grows and grows into its own monster, and the other way to rewards is that the company gets acquired by a large pharmaceutical company or biotech company.
Upvote Downvote

1
Meet Gilead and Sangamo’s Next Big Cancer Collaboration

2018-02-22 247wallst
Sangamo Therapeutics Inc. (NASDAQ: SGMO) shares saw a solid gain early Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences Inc. (NASDAQ: GILD). Specifically, Kite Pharma is collaborating with Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 800677106